5 Stocks That Absolutely Exploded Higher

3. Enliven Therapeutics Inc. (NASDAQ:ELVN)

Enliven Therapeutics rallied for a fourth consecutive day on Friday, climbing 14.30 percent to finish at $46.13 apiece, as investor sentiment was bolstered by the encouraging results from its experimental leukemia drug, ELVN-001.

In an updated report, Enliven Therapeutics Inc. (NASDAQ:ELVN) said that the first phase of the clinical trial showed that 40 percent of the 161 enrolled patients achieved a major molecular response, suggesting that their leukemia levels significantly dropped.

Patients in the 80 mg dose group saw an even better response rate of 48 percent.

Meanwhile, between 22 and 30 percent achieved even deeper responses, suggesting stronger disease control.

“These promising results continue to showcase the consistency of ELVN-001’s overall profile and reinforce its potential to be a best-in-class ATP-competitive inhibitor with differentiated activity relative to allosteric inhibitors,” Enliven Therapeutics Inc. (NASDAQ:ELVN) Chief Medical Officer Helen Collins said.

“In these data, we observed higher response rates in patients treated in earlier lines of therapy, and comparable response rates regardless of prior asciminib exposure. We are also thrilled by the outcome of our recent End-of-Phase 1 meeting with the FDA, where we reached alignment on the 80 mg once daily dose and the inclusion of patients who have received at least one prior TKI in the planned ENABLE-2 Phase 3 trial. This is an important milestone as we advance towards initiating ENABLE-2 later this year,” she noted.